Table 3.
Analysis | No. of trials included | No. of events | RR | 95% CI | P for effect | P for heterogeneity | I 2 (%) | |
---|---|---|---|---|---|---|---|---|
Levosimendan group | Control group | |||||||
Overall | 6 | 33/207 | 39/113 | 0.40 | 0.27–0.59 | <0.001 | 0.79 | 0 |
Placebo‐controlled trials | 3 | 25/136 | 27/57 | 0.40 | 0.26–0.62 | <0.001 | 0.62 | 0 |
Multicentre trials | 3 | 25/136 | 27/57 | 0.40 | 0.26–0.62 | <0.001 | 0.62 | 0 |
Lapse ≤2 weeks | 3 | 17/85 | 21/45 | 0.39 | 0.23–0.65 | <0.001 | 0.58 | 0 |
Lapse >2 weeks | 3 | 16/122 | 18/68 | 0.42 | 0.23–0.74 | 0.003 | 0.55 | 0 |
Study period <6 months | 3 | 23/88 | 24/41 | 0.45 | 0.29–0.69 | <0.001 | 0.46 | 0 |
Study period ≥6 months | 3 | 10/119 | 15/72 | 0.32 | 0.15–0.68 | 0.003 | 0.77 | 0 |
Loading dose used | 2 | 5/48 | 7/39 | 0.43 | 0.16–1.19 | 0.10 | 0.31 | 2 |
Loading dose not used | 4 | 28/159 | 32/74 | 0.39 | 0.26–0.59 | <0.001 | 0.75 | 0 |
Excluding studies providing data via personal communication | 3 | 21/137 | 26/63 | 0.35 | 0.22–0.57 | <0.001 | 0.94 | 0 |
Analysis using inverse variance | 6 | 33/207 | 39/113 | 0.42 | 0.29–0.61 | <0.001 | 0.80 | 0 |
Analysis using Peto | 6 | 33/207 | 39/113 | 0.24a | 0.14–0.44a | <0.001 | 0.83 | 0 |
Analysis using OR | 6 | 33/207 | 39/113 | 0.25b | 0.14–0.46b | <0.001 | 0.85 | 0 |
Analysis using RD | 6 | 33/207 | 39/113 | −0.20c | −0.31 to −0.08c | <0.001 | 0.17 | 36d |
Analysis removing each trial and reanalysing the dataset | P < 0.001, 95% CI <1, and I 2 = 0% for all | |||||||
CI, confidence interval; OR, odds ratio; RD, risk difference; RR, risk ratio.
Peto OR and 95% CI for Peto OR are shown.
OR and 95% CI for OR are shown.
RD and 95% CI for RD are shown.
Data analysed with random‐effects model.